NO20063155L - Anti-IGF-I-reseptorantistoff - Google Patents

Anti-IGF-I-reseptorantistoff

Info

Publication number
NO20063155L
NO20063155L NO20063155A NO20063155A NO20063155L NO 20063155 L NO20063155 L NO 20063155L NO 20063155 A NO20063155 A NO 20063155A NO 20063155 A NO20063155 A NO 20063155A NO 20063155 L NO20063155 L NO 20063155L
Authority
NO
Norway
Prior art keywords
igf
antibodies
receptor
cancer
elevated level
Prior art date
Application number
NO20063155A
Other languages
English (en)
Norwegian (no)
Inventor
Rajeeva Singh
Daniel J Tavares
Nancy E Dagdigian
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of NO20063155L publication Critical patent/NO20063155L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
NO20063155A 2003-12-08 2006-07-07 Anti-IGF-I-reseptorantistoff NO20063155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody
PCT/US2004/038230 WO2005061541A1 (en) 2002-06-14 2004-12-07 Anti-igf-i receptor antibody

Publications (1)

Publication Number Publication Date
NO20063155L true NO20063155L (no) 2006-08-11

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063155A NO20063155L (no) 2003-12-08 2006-07-07 Anti-IGF-I-reseptorantistoff

Country Status (13)

Country Link
EP (1) EP1692176A4 (de)
JP (1) JP2008502589A (de)
KR (1) KR20070001883A (de)
CN (1) CN1886424A (de)
AU (1) AU2004303792A1 (de)
BR (1) BRPI0417406A (de)
CA (1) CA2548065A1 (de)
CR (1) CR8426A (de)
EA (1) EA009807B1 (de)
EC (1) ECSP066595A (de)
IL (1) IL174770A0 (de)
MX (1) MXPA06005540A (de)
NO (1) NO20063155L (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
EP2569012A4 (de) * 2010-05-11 2013-10-30 Aveo Pharmaceuticals Inc Anti-fgfr2-antikörper
EP2766478A4 (de) 2011-10-10 2015-06-17 Los Angeles Childrens Hospital Neue asparaginase und verfahren zur behandlung von erkrankungen im zusammenhang mit asparaginabhängigkeit
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
IL270971B1 (en) * 2017-05-30 2024-02-01 Teijin Pharma Ltd Antibody against the 1-IGF receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU768329B2 (en) * 1998-12-04 2003-12-11 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor alphavbeta3
HUP0302525A2 (hu) * 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
MXPA05008617A (es) * 2003-02-13 2005-11-04 Pfizer Prod Inc Usos de anticuerpos anti-receptor del factor de crecimiento semejante a la insulina i.

Also Published As

Publication number Publication date
KR20070001883A (ko) 2007-01-04
CA2548065A1 (en) 2005-07-07
ECSP066595A (es) 2006-10-17
AU2004303792A1 (en) 2005-07-07
EP1692176A1 (de) 2006-08-23
EA009807B1 (ru) 2008-04-28
MXPA06005540A (es) 2006-08-17
CN1886424A (zh) 2006-12-27
EA200600931A1 (ru) 2006-10-27
IL174770A0 (en) 2006-08-20
EP1692176A4 (de) 2008-11-12
BRPI0417406A (pt) 2007-04-03
CR8426A (es) 2007-12-04
JP2008502589A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
Subbiah et al. Multimodality treatment of desmoplastic small round cell tumor: chemotherapy and complete cytoreductive surgery improve patient survival
Ristau et al. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research
Fong et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer
Wernicke et al. Prostate‐specific membrane antigen expression in tumor‐associated vasculature of breast cancers
Dorff et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer
EP1996716A4 (de) Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
EA200970130A1 (ru) Антагонистическое антитело для лечения рака
Errarte et al. The expression of fibroblast activation protein in clear cell renal cell carcinomas is associated with synchronous lymph node metastases
WO2006099141A3 (en) Anti-mesothelin antibodies
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
BR112012021941A2 (pt) Proteínas terapêuticas de ligação a dll4
UA106492C2 (uk) Імунокон'югати анти-мезотеліну, їх застосування та одержання
MX2009012838A (es) Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2007149948A3 (en) Compositions and methods for diagnosis and treatment of tumors
NO20063155L (no) Anti-IGF-I-reseptorantistoff
EA200601405A1 (ru) Гуманизированное антитело
WO2005094348A3 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
Dimitrakopoulos et al. NSCLC and the alternative pathway of NF-κB: uncovering an unknown relation
EP1539818A4 (de) Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
Zhu et al. Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis
WO2008131575A3 (en) Anti-alk antibodies suitable for treating metastatic cancers or tumors
Pawlikowski et al. Overexpression of prothymosin alpha is related to pituitary adenoma recurrence but not to adenoma invasiveness and proliferation
ATE288960T1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application